AMIKACINE STRAGEN 250 mg/ml, solution for injection 10 bottles of 2 ml
Active ingredients: Amikacin, Amikacin sulfate
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection10 bottles of 2 mlintramusculaire;intraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- AMIKACINE STRAGEN 250 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intramusculaire;intraveineuse
- Presentation description
- 10 flacons en verre de 2 mL
- Marketing authorisation holder
- STRAGEN-FRANCE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 23 Apr 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63899393CIP73032728CIP133400930327289Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SULFATE D'AMIKACINEsolution | — | SA |
| AMIKACINEsolution | 250 mg · 1 mL de solution | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.